1. Home
  2. LXRX vs GCMG Comparison

LXRX vs GCMG Comparison

Compare LXRX & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • GCMG
  • Stock Information
  • Founded
  • LXRX 1995
  • GCMG 1971
  • Country
  • LXRX United States
  • GCMG United States
  • Employees
  • LXRX N/A
  • GCMG N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • GCMG Finance/Investors Services
  • Sector
  • LXRX Health Care
  • GCMG Finance
  • Exchange
  • LXRX Nasdaq
  • GCMG Nasdaq
  • Market Cap
  • LXRX 541.5M
  • GCMG 611.5M
  • IPO Year
  • LXRX 2000
  • GCMG N/A
  • Fundamental
  • Price
  • LXRX $1.34
  • GCMG $10.65
  • Analyst Decision
  • LXRX Buy
  • GCMG Buy
  • Analyst Count
  • LXRX 5
  • GCMG 3
  • Target Price
  • LXRX $3.23
  • GCMG $15.67
  • AVG Volume (30 Days)
  • LXRX 2.3M
  • GCMG 882.1K
  • Earning Date
  • LXRX 11-06-2025
  • GCMG 11-05-2025
  • Dividend Yield
  • LXRX N/A
  • GCMG 4.51%
  • EPS Growth
  • LXRX N/A
  • GCMG N/A
  • EPS
  • LXRX N/A
  • GCMG 0.32
  • Revenue
  • LXRX $70,864,000.00
  • GCMG $543,085,000.00
  • Revenue This Year
  • LXRX $66.55
  • GCMG $4.88
  • Revenue Next Year
  • LXRX N/A
  • GCMG $11.59
  • P/E Ratio
  • LXRX N/A
  • GCMG $33.25
  • Revenue Growth
  • LXRX 1255.21
  • GCMG 17.40
  • 52 Week Low
  • LXRX $0.28
  • GCMG $10.54
  • 52 Week High
  • LXRX $1.66
  • GCMG $14.48
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 44.82
  • GCMG 15.80
  • Support Level
  • LXRX $1.36
  • GCMG $10.93
  • Resistance Level
  • LXRX $1.52
  • GCMG $11.27
  • Average True Range (ATR)
  • LXRX 0.13
  • GCMG 0.18
  • MACD
  • LXRX -0.01
  • GCMG -0.08
  • Stochastic Oscillator
  • LXRX 32.61
  • GCMG 8.44

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

Share on Social Networks: